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Abstract : Costs of drugs used for the treatment for 1 year were examined in 32 pa-
tients with asthma in relation to disease severity. Asthma severity was classified as :
1) intermittent; 2) mild persistent; 3) moderate persistent; 4) severe persistent. 1.
The total cost of drugs used for each patient for 1 year was the highest (¥ 263,710)
in patients of stage 4 (severe persistent) and the lowest (¥ 74,670) in those of stage
1 ( intermittent). The costs of bronchodilators and antiallergics were predominant at
all stages, and their cost increased significantly with increasing severity. 2. The costs
of drugs such as antiallergics and bronchodilators were predominant, and the costs of
drugs such as inhaled corticosteroids and mucolytics were considerably high in pa-
tients of all stages. 3. The costs of bronchodilators, inhaled corticosteroids, and
antiallergics were the largest in patients of stage 4. The results suggested that the
costs of drugs used for the asthma treatment tended to increase as the disease sever-
ity became stronger from stage 1 to stage 4, and the main drugs related to the in-
crease in total costs were bronchodilators, antiallergics, and inhaled corticosteroids.
Key words : asthma, disease severity, costs, bronchodilators, corticostreroids,
antiallergics
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Introduction
Asthma is one of the most popular respiratory
diseases. In the onset mechanisms of asthma,
IgE-mediated allergy plays an important role, in
which an increase in the generation of leukotriene
C4 (LTC4) related to brponchospasm"3l, and
leukotriene B4 (LTB4) related to bronchial
hyperresponsiveness" 6l , is observed. The leuko-
cytes of the asthmatics generated significantly
more LTB4 and LTC4 than those of controls.
The leukocytes of patients with atopic asthma
generated significantly more LTC4 than those of
patients with nonatopic asthma. In addition, it
has been reported that there is a significant
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correlation between LTB4 generation by leuko-
cytes and the degree of bronchial hyperrespon-
siveness to methacholine 6) • However, the
pathogenesis of asthma becomes somewhat com-
plex with aging. Our previous studies have
shown that bronchial hyperresponsiveness de-
creases significantly as age at onset increases in
patients without a family history, suggesting
that the hyperresponsiveness shows a tendency
to decrease with aging 7) •
The process of development of drugs for the
treatment of asthma has shown that asthma
symptoms could be improved more easily with
newly developed drugs such as inhaled corticos-
teroids and bronchodilators. However, the costs
of drugs newly developed are considerably high,
and the number of patients with asthma has
been increasing in recent years. Because of
high cost of newly developed drugs and an in-
crease in number of patients with asthma, it
has been suggested that the costs of medication
for the treatment of asthma has been increasing.
In recent years, several pharmacoeconomic
studies in asthma have been conducted in the
USA8 -10) and Europe Jl -14l • In the present study,
the costs of drugs used for the treatment of
asthma was studied in relation to disease severity.
Subjects and Methods
The subjects of this study were 32 patients
(18 females and 14 males) with asthma. Their
mean age was 66.2 years (range 48-76 years).
All patients were treated with antiasthmatic
drugs such as bronchodilators, corticosteroids,
antiallergics, mucolytics, antibiotics, and others
(physiological saline, drugs for common cold,
etc) at Misasa Medical Center for 1 year. The
costs of drugs used for the treatment of asthma
per patient for 1 year (from January to Decem-
ber in 2000) were calculated. The total costs of
all drugs and the cost of each drug were ex-
pressed throughout in ¥.
Asthma severity was evaluated according to
international guidelines'S). Assessments of sever-
ity were classified as : 1) intermittent; 2) mild
persistent; 3) moderate persistent; 4) severe
persistent. The costs of drugs used per patient
for 1 year were compared among four stages.
Statistically significant differences of the mean
were estimated using unpaired Student's t test.
A p value of <O. 05 was regarded as significant.
Results
The total costs of drugs used for patients of
stage 1 and 2 were significantly lower than in
those of stage 3 and stage 4. The costs of
drugs such as bronchodilators, corticosteroids,
antiallergics, mucolytics, antibiotics, and others
tended to increase as stage of asthma went
up, as shown in Table 1. Of all drugs used for
Table 1. Costs of drugs used for treatment per patient for 1
year in relation to asthma severity
Drugs Asthma stage
------
4
Bronchodilators 20,200 29,170 56,170 55,140
Corticosteroids 9,950 15,280 27,070 34,930
Antiallergics 30,570 56,440 111,170 130,210
Mucolytics 12,700 15,820 18,630 19,460
Antibiotics 820 3,420 9,480 20,780
Others 440 1,670 1,640 3,190
Total 74,670 ab 121,780 crl 224,160 at 263,710 bd
Data are presented as mean¥. 8,h and d: p<O.OOI, c:p<O.Ol.
asthma treatment, the costs of antiallergics and
bronchodilators were markedly large, and the
costs of corticosteroids and mucolytics were
considerably high in patients of all stages (Ta-
ble 2).
,------------------------------------------------- ----------
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Table 2. Total costs of each drug used for the treatment per
patient for 1 year in all stages Asthma
stage o 10 20 30 (%)
Drugs Costs( ¥) %
Bronchodilators 38,946 23.2
Corticosteroids 20,712 12.4
Antiallergics 81,708 48.8
Mucolytics 17,251 10.3
Antibiotics 7,094 4.2
Others 1,765 1.1
Total 167,476 100.0
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Fig.2a. The proportion of the cost of corticosteroids
against total drugs in each asthma type
Fig.l a. The proportion of the cost of bronchodilators
against total drugs in each asthma stage
patient of all stages was the largest in those of
stage 4 (Fig. 1 b). The proportion of the cost
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Fig.2b. The proportion of the cost of corticosteroids used
in patients of all stages
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proportion of the cost of antiallergic agents in
total drugs in each asthma sage tended to in-
crease as the asthma stage went up from 1 to
4 (Fig. 3 a). The proportion of the cost of
antiallergics used in patients of all satges was
atages was the largest in those of stage 4, and
the lowest in those of stage 1 (Fig. 2 b). The
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The proportion of the cost of bronchodilators
in total drugs in each asthma stage was the
largest in patient with stage 1 and the lowest in
those of stage 4 (Fig. 1 a). However, the pro-
portion of the cost of bronchodilators used in
Asthma
stage o 10 20 30 40
(%)
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Asthma
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Fig.l b. The proportion of the cost of bronchodilators used
in patients of all stages
Fig.3a. The proportion of the cost of antiallergies against
total drugs in each asthma type
of corticosteroids in total drugs in each asthma
stage was not different among patients of four
stages (Fig. 2 a). In contrast, the proportion of
the cost of corticosteroids used in patients of all
the largest in those of stage 4, and showed a
tendency to decrease as the asthma stages went
down (Fig. 3 b).
15 Costs of drugs used for asthma treatment
Fig.S. The proportion of the cost of antibiotics against
total drugs in each asthma type
Discussion
Many antiasthmatic drugs such as inhaled
sympathomimetics, inhaled corticosteroids and
leukotriene C4 receptor antagonists have been
developed in recent years. However, the costs
of these newly developed drugs are in general
considerably high. Particularly, the use of pre-
scribed inhaled sympathomimetics and
corticosteroids has been increase with severity
of illness 8,9). In addition, the number of pa-
tients with asthma, particularly, of elderly asth
matics, has been increasing in recent years in
Japan. It has been also reported that pharmaco-
therapy for asthma is underused or inadequate.
In particular, treatment with inhaled corticos-
teroids is insufficient. In contrast, short-term
sympathomimetics are exessively prescribed.
Only one-third of asthma patients were treated
according to asthma guidelines.
A relationship between total costs for asthma
treatment and disease severity has been dis-
cussed in recent years. The most empirical data,
for 1995-1996, clearly showed an increased costs
depending upon illness severity16) , and other re-
ports have also shown an enormous increase as
total costs as asthma severity increases 6 -12.15.m •
In this study, the costs of drugs used for the
treatment of asthma were examined in 32 pa-
tients with asthma. The results obtained here
demonstrated that the total costs of drugs for
asthma increased as disease severity increased
from stage 1 to stage 4. Regarding the propor-
tion of the costs of each drug against total
drugs in each asthma stage, the proportion of
costs of antiallergics and antibiotics increased.
In contrast, the proportion of costs of
bronchodilators and mucolytics decreased, and
the proportion of the costs of corticosteroids did
not change, as asthma severity increased from
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Fig.4. The proportion of the cost of mucolytics against
total drugs in each asthma type
Stage 3
Stage 2
Fig.3b. The proportion of the cost of antiallergics used in
patients of all stages
The proportion of the cost of mucolytics in to-
tal drugs in each asthma stage was the largest
in patients of stage 1 and the lowest in those of
stage 4 (Fig. 4). In contrast, the proportion of
the cost of antibiotics in total drugs in each
asthma stage was the largest in patient of stage
1, and the proportion tended to increase as the
asthma stage went up from 1 to 4 (Fig. 5).
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stage 1 to stage 4. This suggests that the pro-
portion of the costs of antiallergics and antibod-
ies against total drugs was the largest, and the
proportion of bronchodilators and mucolytics
against total drugs was smallest in patients of
stage 4 (severe persistent). The proportion of
the costs of each drug used in patients of all
stages tended to increase as asthma stage went
up from stage 1 to 4. The results reveal that
the costs of bronchodilators, corticosteroids,
and antiallergics increased as asthma severity
became stronger.
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気管支嘱息に対する年間薬剤費の重症度別検討
谷崎勝朗,光延文裕,保崎泰弘,芦田耕三,
清田全紀1),岩垣尚史,藤井 誠,高田真吾
岡山大学医学部 ･歯学部附属病院三朝医療センター
内科, 1)リハビリテーション科
気管支嘱息32例を対象に,治療のために要した
年間薬剤費を,国際ガイドラインの重症度分類
(stage1-4)により検討した｡ 1.年間の総薬
剤費はstage4の症例で最も高く (平均¥284,370),
17.SzucsTD,AnderhubH,RutishauerM:
¶1eeconomicbrudenpofas山ma:directand
indirectcostsinSwitzerland.EurRespirJ
13:281-286,1999.
-万,stagel(平均¥74,670)で最も低い値を示
した｡2.個々の薬剤費の検討では,抗アレルギー
秦,気管支拡張薬などの薬剤費が高く,次で副腎
皮質ホルモン (主として吸入薬),去疾薬の順で
あった｡3.気管支拡張薬,副腎皮質ホルモン,
抗アレルギー薬などの薬剤費は,いずれもstage
4で最も高い値を示した｡
気管支晴息に対する薬剤費は,疾患が重症にな
るにつれて高くなる傾向を示した｡また,その主
たる薬剤は気管支拡張薬,抗アレルギー薬,吸入
用副腎皮質ホルモンなどであった｡
